The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Doctor asks when profit becomes profiteering after Retrophin raises drug price by 20 times.
As life expectancies increase, RealMoney Pro contributor Chris Versace reveals ways investors can play the aging U.S. population.
Investors will get a first look at data from an early stage study of an Applied Genetic therapy on Friday.
Keryx Biopharmaceuticals (KERX) shares are declining after being downgraded to 'underperform' by analysts at FBR Capital on Monday.
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Tesla may currently trade at a high multiple to both earnings and sales, but the revolutionary electric car-maker will grow into its rich valuation.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Merck will sell the skin cancer drug under the brand name Keytruda.
Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer.
With Ampion failure, Ampio's pipeline is worthless.
Infinity and Abbvie will jointly develop and market duvelisib.
Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.
Sales of Spectrum's drug Fusilev for patients with metastatic colorectal cancer remain strong heading into the remainder of 2014.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV